Contamination Risk Assessment in Aseptic, Non-Sterile and Terminally Sterilized Products March 7 th & 8 th Raleigh, NC

Similar documents
Strategy for Investigating Microbial Contaminations

Auditing Microbiology Media Suppliers

Key Elements of a Microbial Contamination Control Policy Why and how to write a policy for Microbial Contamination Control

Stability Testing for Pre-Clinical and Early Phase Clinical Drug Products

Microbial Detection Methods and Their Limitations

Disinfectant Qualification Bacteria, Fungi, Viruses and Atypical Organisms A Step by Step Workshop

Chemical Sterilization - Alternate Sterilization Methods

MICROBIAL LIMIT TESTS FOR RAW MATERIALS AND NON-STERILE PRODUCTS REVIEW-DISCUSSIONS-INTERPRETATIONS

Facility Water Management

Filling and Packaging Validation for FDA Regulated Industries

Overview of a sterility assurance program for PET drugs

NEW! Processing of cgmp Controlled Raw Materials

Microbiological Consideration for Non-Sterile Pharmaceutical

General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT

Disinfectant Qualification A Multifaceted Study

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

Aseptic Processing Current Issues & Trends

Application of Quality Risk Management Tools for Cell Therapy Manufacturing

On-Site GMP Training GMP COMPLIANCE TECHNICAL

UNIT 1: VARIATION IN PRODUCTION SYSTEMS

FDA s Guidance for Industry

Aseptic Process Validation

EFFECTIVE CLINICAL TRIALS. NUSAGE PharmEng. Pharmaceutical and Biotechnology Training Program. Copyright 2014 NUSAGE-PharmEng.

Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)

SPEAKER WHY YOU SHOULD ATTEND. One and a Half Day In-Person Seminar: Location: Los Angeles, CA May 24-25, 2018

A.1 Contents file 4 to 5 A.1 (1)

MINIMUM REQUIREMENTS FOR A VENDOR

Microbiology Research Associates

Isolators v. RABS: Facility Design Considerations for a Fill-Finish Finish Suite

Metrics in Microbiology Monitoring Practices

PhEn-602 Notes # 4 J. Manfredi

CLINICAL TRIAL BILLING COMPLIANCE BOOT CAMP

Tests to Support Sterility Claim. Imtiaz Ahmed

USP <1116> and Contamination

Quality is Our Promise.

Microbiological Cleaning Method Validation

EU and FDA GMP Regulations: Overview and Comparison

ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers

The Parenteral Drug Association

GMP In-house Training

sterility assurance Prove the power and your processes

Media Fill A Process Simution. Presented By Shikha Chauhan

Is it true, Annex 1 revision will have no impact on resources or cost? Walid El Azab Technical Service Manager STERIS

for IND and RDRC Regulated PET Compounding

Review Validation of aseptic processes for pharmaceuticals

Taking a Leap Toward Global Supply Chain Efficiency - Part II

Process Validation for Active Pharmaceutical Ingredients (API)

MEDICAL DEVICE DESIGN Implementing An Approach CONTROL I. Design control in both QSR and ISO 13485:2003 is complicated. Regardless of the complex

GMP On Site Series. GMP Essentials

Inspections, Compliance, Enforcement, and Criminal Investigations

Annex A2. Guidance on Process Validation Scheme for Aseptically Processed Products

WHO PUBLIC INSPECTION REPORT (WHOPIR) Quality Control Laboratory

This compilation of the complex

Julie Roberts. Audit hot Topics and Regulatory Requirements

a n d B i o s a fety C o n s i d e ra t i o n s

Whitepaper. High temperature HEPA filtration. Dr.-Ing. Marc Schmidt, Dr.-Ing. Lothar Gail, Hugo Hemel MSc. Preview

EXHIBITOR PROSPECTUS

COurse. Estimation: June 24-25, 2014 JW Marriott Houston, TX. EUCI is authorized by IACET to offer 1.4 CEUs for the course.

Update to the Manufacturing Principles for Medicinal Products

Semiconductor Manufacturing Facility Design

AAAA Management Seminar: Benefits-Based Pricing Solutions

Managing Your Environmental Isolates

Portfolio Management Professional

Current Trends in Sterile Manufacturing. by Sterling Kline, RA Director of Project Development Integrated Project Services (IPS)

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

FACILITATED by. General Manager. This is a 2-1/2 day. Jeff s responsibility during this course is to JEFF SACKS. Workshop.

Managing Risk in Your P2P Process: 10 Ways that Automation Can Help Mitigate Risk

Electronic Components Basics

Guidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE

Republic of the Philippines Department of Health OFFICE OF THE SECRETARY M a n i l a

GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS

Hot Topics in Drug Product Process Validation: A Reviewer s Perspective

Single-Use Final Fill: Benefits and Considerations

RPL Record of Evidence Supporting application for

Hosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil)

PROJECT PORTFOLIO MANAGEMENT

Title (Mr., Miss, Mrs., etc.): Last Name: First Name: Middle Name: Suffix (II, Jr., etc.): Maiden/Previous Last Name:

Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials

Advanced Well Integrity Management

Leachables & Extractables

Guiding Principles for the implementation of fluid management technologies for modern single use aseptic processing


ISO 9001: Major Revision, Significant Changes

Course ID: WAPOL October 27, 8:30 A.M. to 5 P.M. Hampton Inn - Richland 486 Bradley Blvd. Richland, WA (509)

Trinity College Dublin QP Forum 2017 Tuesday 25 th April

KINGSMANN CARE GROUP

Inventory Control/Warehouse Operations Seminar

Operational Excellence:

Harmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities. Plus an update on PET Drug User Fees

Learn to Inspire Peak Performance of Your People

Actavis Italy. Nerviano Plant

Retail Channel Management and Corporate Operations. Microsoft Dynamics AX 2012 R3

Current Topics For Sterile Generic Drug Products

AIChE ANNUAL MEETING OCTOBER 29 - NOVEMBER 3, 2017 MINNEAPOLIS, MN SPONSORSHIP OPPORTUNITIES

FOREWORD. Dear colleagues,

From employee to executive

Supplier Assurance Program. CBE Pty Ltd

TERMS AND DEFINITIONS

Computer Validation - Introduction to Risk Management - The GAMP 5 Approach

EXHIBITOR OPPORTUNITIES

Transcription:

Contamination Risk Assessment in Aseptic, Non-Sterile and Terminally Sterilized Products March 7 th & 8 th Raleigh, NC Contamination risk levels differ in aseptic, and non-sterile and terminally sterilized products. Within the non-sterile products risk levels vary per mode of administration. In terminally sterilized products, contamination for a terminally sterilized medical device may differ from a terminally sterilized drug product. Contamination risk in a non-sterile drug product may be different for a healthy patient as compared to an immunocompromised patient or children. Contamination risk assessment initially begins with understanding the nature of a product, release specifications and which organisms are objectionable. In some medical device manufacturing, particulate contamination could also be objectionable because of the electronics involved. The manufacturing facility is designed to mitigate and reduce contamination risks. Facility controls vary depending upon final product requirements. Contamination may also result due to inadequate cleanroom/rabs/isolator/design and maintenance. Similarly, if a risk based approach is not adopted right from the beginning, contamination risks can occur due to utilities, raw materials, excipients, process and also inadequate testing. With ICH Q9, Q10, ISO and EU all aligned on a risk based approach; it is time to explore performing a real risk assessment to control contamination in your product. In this two day workshop, Microrite experts will address how to perform contamination risk assessment in sterile, various non-sterile and terminally sterilized drugs and devices. Which industries does this workshop apply to? Pharmaceuticals, Biotechnology, Medical Device, and In Vitro Diagnostics, Nutraceuticals and Pharmacies Who will benefit? QC Microbiologists, Manufacturing, Quality Assurance, Validation, Facilities and Training

Overview Cleanroom Requirements for Aseptic Facilities Discussion of the various guidances on facility design and operations for aseptic facilities Misunderstandings in interpretation of these guidances and standards Common errors in airflows and airflow pattern analysis Barrier systems Commonly observed deficiencies in barrier systems such as open/closed RABs and Isolators that can lead to contamination Understanding airflows and contamination risks when operating in RABs and Isolators Why airflows adequate during certification testing, but environmental monitoring, media fill and batch failures are persistent Understand the sources of EM excursions in RABs or ISO 5/7 or Grade A/B areas Risk Based Monitoring of Aseptic Facilities-A Paradigm Shift Monitoring of Cleanrooms for Aseptically manufactured products-what you should know and understand before and after qualification Discrepancies between standards and guidances for monitoring aseptic environments Choice of equipment-what you should know o Non-Viable particle monitoring o Viable particle monitoring Learn about the design of monitoring equipment to avoid errors Common errors companies make during choice and set up of monitoring devices Cleanroom Requirements for Manufacture of Terminally Sterilized Drugs and Devices Depending upon the process, pre-sterilization bioburden and the method of sterilization, facility requirements may vary Though strict facility controls and barrier systems may not be required for such products, performing a risk assessment is the correct choice when designing facilities for manufacture or terminally sterilized products Discussion of cleanroom guidances and standards pertinent for terminally sterilized products How should facilities with relatively low contamination risk be maintained Risk Based Monitoring for Terminally Sterilized Products Discussion of standards for monitoring of facilities making terminally sterilized products How to set limits as such standards do not have limits for viable particles Performing risk assessment to select sites, importance of trending organisms that may be difficult to sterilize Facility Controls for Non-Sterile Products Level for allowable bioburden in non-sterile product varies; though some products may require limited facility controls, others need considerable controls Adopting a risk based approach using the product s inherent anti-microbial properties, facility costs may be reduced How should such moderately to minimally controlled environments be maintained Discussion on guidances related to non-sterile facilities, especially oral dosage forms Risk Based Monitoring for Non-Sterile Products Non-viable particulates may not be a concern in non-sterile products, once classified facilities should be monitored to meet class requirements Monitoring for viable organisms is critical in all non-sterile facilities, with special attention on those objectionable in the product via mode of administration Learn how to set up a risk based EM program considering that product bioburden cannot exceed specifications and the product is void of objectionable microorganisms Discussion on how to use product characteristics to adjust frequency of monitoring

Overview Continued Water Quality Risk Assessment Learn how to perform risk assessment for quality of water used for process, equipment cleaning and cleaning of facilities depending upon the final product release criteria Learn how to choose which ports to test at what frequency to avoid onerous sampling while evaluating water quality consistently Asses water quality risk by understanding biofilm formation and endotoxins Assessing Risk of Added Gases Understand the contamination risks that each type of process gas poses to product Depending upon the risk, develop a monitoring program; evaluate the risk of aerobes and anaerobes Evaluate contamination risk of anaerobes and document rationale when anaerobes are not tested Gowning requirements for Aseptic, Non-Sterile and Terminally Sterilized Products Understanding garment/supplier selection as well as garment cleaning, sterilization and testing Develop a risk based gowning program Learn about the various standards that gown suppliers are required to adhere to Audit and conduct surveillance according to these standards Gown qualify and monitor gowning practices of personnel to protect product Process Risk Assessment In aseptic operation; every equipment setup, assembly, adjustment, operation, aseptic connections, interventions and environmental monitoring is a contamination risk Learn how to identify and mitigate risk In terminally sterilized product, contamination risk exists due to predominance of certain microorganism, inadequate facility controls and maintenance, and microbial quality of materials and components In non-sterile products contamination risk during processing is critical as well as microbial reduction methods should be a part of process risk assessment Learn about the critical control points in each type of product by understanding where and how contamination can enter and proliferate Understand what level of contamination can be allowed in what step of the process and is contamination reduction strategies such as cleaning, cleaning validation, sterile filtration, or drying are adequate for the level of risk. Assessing Risk during testing False positive and false negative laboratory testing results can lead to loss of product or risk to patient Learn how to perform risk assessment in laboratory operations and testing: o Media o Test methods o Method validation o Laboratory facilities o Proficiency

PROGRAM March 7 th & 8 th B-Tec Golden LEAF BTEC 850 Oval Drive, Suite 195 Raleigh, NC 27606 (919) 513-2000 http://www.btec.ncsu.edu/index.php Day 1 Agenda Registration and fast Cleanroom Requirements for Aseptic Facilities & Risk Based Monitoring of Aseptic Facilities-A Paradigm Shift Cleanroom Requirements for Manufacture of Terminally Sterilized Drugs and Devices & Risk Based Monitoring for Terminally Sterilized Products Lunch Facility Controls for Non-Sterile Products Risk Based Monitoring for Non-Sterile Products Questions and answers Day 2 Agenda fast Water Quality Risk Assessment & Assessing Risk of Added Gases Gowning requirements for Aseptic, Non-Sterile and Terminally Sterilized Products Lunch Process Risk Assessment Assessing Risk during testing Questions and answers and discussions 8.00 AM to 8.30 AM 8.30 AM to 10.00 AM 10.00 AM to 10.15 AM 10.30 AM to 12.00 AM 12.00 PM to 1.00 PM 1.00 PM to 3.00 PM 3.00 PM to 3.15 PM 3.15 PM to 4.15 PM 4.15 PM to 5.00 PM 8.00 AM to 8.30 AM 8.30 AM to 10.00 AM 10.00 AM to 10.15 AM 10.30 AM to 12.00 AM 12.00 PM to 1.00 PM 1.00 PM to 3.00 PM 3.00 PM to 3.15 PM 3.15 PM to 4.15 PM 4.15 PM to 5.00 PM

REGISTRATION FORM Personal Information of One Registrant Last Name: Mr. Ms. Dr. First Name: Job Title: Organization: Mailing Address: Telephone: Email: Fee: $1800.00 per attendee (Includes 2 day workshop fee, breakfast, lunch, break, and course material) Additional Attendees Method of Payment: Credit Card and Check payments only. Attendees can register and make payments on Microrite s website-www.microrite.com or complete this form and fax to 408-445-1236. Check payments must be cleared before the workshop date. If you have any questions regarding payment methods feel free to contact Microrite at 408-445-0507 or send your enquiry to labraham@microrite.com. Confirmation of registration will be sent via email. For credit card payment on website, a payment receipt will be considered as confirmation of registration. For credit card information faxed to Microrite an email confirmation will be sent with a copy of payment receipt. Please call 408-445-0507 in due time if confirmation is not received after payment. Workshop cancellation must be received 10 business days prior to the workshop less a 10% service fee, cancellation requests will be accepted via email only. The organizations primary contact or credit card holder must make all refund requests. Refunds will be credited to the original credit card used to purchase the workshop..

PAYMENT INFORMATION Choose One (Place X) VISA Master Card American Express Card Holder s Name Address of Card Holder: Enter firm address for corporate card or personal address for personal card Street: City/State: Zip Code: Country: Contact Ph No & Email: Card Number: Expiration(Month/Year): Amount (US Dollars): Signature: Name of Attendee(s) Referred by: Kindly note the name of the company or person that referred you to this workshop. We would like to thank them..

About the Presenter Ziva Abraham is the President and Founder of Microrite, Inc., a California based consulting firm providing consulting and training services to pharmaceuticals, biotechnology, medical devices and in vitro diagnostics in the areas of quality assurance, quality control, microbiology, and validation. Ziva has over 25 years of academic, research, clinical and industrial experience in microbiology, and quality assurance. Ziva has received her Master s Degree in microbiology with a focus on Mycology and has conducted research on developing microbial Insecticides using entomogenous bacteria and fungi. Her career also includes founding and managing clinical laboratories for Maccabi Medical in Israel. She has trained personnel from various industries in microbiology techniques and methods. She uses her extensive experience to teach why assessing risk of microbial contamination should be in the forefront of any company that has products for human/veterinary use. Her experience in clinical laboratories has provided her with the framework to understand the effects of microbial contamination in products from a patient safety perspective. Morgan Polen has been involved with cleanrooms and contamination control since 1984. He has Worked in over 40 countries involved with projects ranging from cleanroom design, construction, validation, monitoring program development, particle counter design and product management for cleanroom related products and systems. He has addressed monitoring and control solutions in a wide variety of clean industries such as pharmaceutical, medical device, semiconductor, data storage, aerospace, defense, automotive, optical and others. Company Microrite s goal is to provide practical solutions through consulting and training Consulting Services Microrite is a San Jose, CA based Consulting Company helping Pharmaceuticals, Biotechnology, Medical Devices, In-Vitro Diagnostics and Combination products in the areas of Quality Assurance, Microbiology, Process Development, Process Validation, Facility and Utility Validation Visit www.microrite.com to learn more about us